Wegovy works primarily by acting on your brain to reduce hunger and make you feel full sooner. It’s a synthetic version of a hormone your gut naturally releases after eating, called GLP-1, but it’s engineered to last much longer in your body. The result: you eat less because you genuinely want less food, not because you’re white-knuckling through smaller portions.
How It Targets Your Brain’s Appetite Centers
Your body produces GLP-1 in small bursts after meals. It signals your brain that food has arrived and you can stop eating. Wegovy (semaglutide) mimics this hormone but at much higher, sustained levels, activating GLP-1 receptors across several brain regions that control hunger, fullness, and food reward.
The most important action happens in two areas. First, in the hypothalamus, Wegovy activates neurons that promote satiety while simultaneously quieting neurons that drive hunger. This shifts the balance so your baseline appetite drops. You’re not fighting cravings with willpower; the cravings themselves are dialed down. Second, Wegovy acts on reward-related brain regions, including areas involved in motivation and pleasure-seeking behavior. This is why many people on the medication report that food simply becomes less interesting. The mental “noise” around eating, the constant thinking about snacks, the pull toward high-calorie foods, gets quieter.
Importantly, Wegovy doesn’t easily penetrate deep into most brain tissue. Instead, it accesses specific entry points near the brainstem and base of the brain where the blood-brain barrier is naturally thinner. These circumventricular areas act as gateways, allowing the drug to influence appetite circuits without needing to flood the entire brain.
Slower Digestion Keeps You Full Longer
Beyond the brain, Wegovy slows the rate at which your stomach empties food into your small intestine. When food sits in your stomach longer, stretch receptors keep sending “I’m full” signals to your brain well after a meal. A smaller lunch might keep you satisfied for four or five hours instead of two.
This delayed gastric emptying is also the source of the drug’s most common side effects. Nausea, bloating, and occasional vomiting happen because the stomach isn’t clearing as quickly as your body expects. For most people these symptoms are mild and fade over time, particularly with the gradual dose increases built into the treatment schedule. In rare cases, the slowdown can become extreme, leading to a condition called gastroparesis, where the stomach struggles to empty at all.
Effects on Blood Sugar and Metabolism
Wegovy also influences how your body handles blood sugar, which has indirect effects on weight. It boosts insulin release when blood sugar rises after a meal, helping your cells absorb glucose more efficiently. At the same time, it lowers glucagon, a hormone that tells your liver to dump stored sugar into the bloodstream. The net effect is more stable blood sugar levels, which means fewer energy crashes and less of the rebound hunger that follows a blood sugar spike. Notably, this insulin boost only kicks in when blood sugar is actually elevated, which makes the drug unlikely to cause dangerous drops in blood sugar on its own.
How Much Weight People Typically Lose
In a major 68-week clinical trial of nearly 2,000 adults, Wegovy was used alongside a reduced-calorie diet and increased physical activity. While individual results vary widely, the drug consistently produces significantly more weight loss than diet and exercise alone. The FDA approved it specifically for adults with obesity (BMI of 30 or higher) or adults with a BMI of 27 or higher who have at least one weight-related health condition such as high blood pressure or high cholesterol. It’s also approved for adolescents aged 12 and older with obesity.
Beyond weight, the SELECT trial found that Wegovy reduced the risk of major cardiovascular events, including heart attacks and strokes, by 20% in people with pre-existing heart disease who were overweight or obese but did not have diabetes. This was a significant enough finding that the FDA expanded the drug’s approved uses to include cardiovascular risk reduction.
The Dose Escalation Schedule
You don’t start at the full dose. Wegovy uses a 16-week ramp-up designed to let your body adjust and minimize gut side effects. You begin with a 0.25 mg injection once a week for the first four weeks, then increase to 0.5 mg, then 1 mg, then 1.7 mg, each step lasting four weeks. By week 17, you reach the maintenance dose of 2.4 mg (or 1.7 mg if the higher dose isn’t tolerable). If side effects are rough at any step, your prescriber can hold you at that dose for an extra four weeks before moving up.
The injection is subcutaneous, meaning it goes just under the skin of the abdomen, thigh, or upper arm. It’s done once weekly on the same day each week, though the specific day can be changed if needed.
What Happens When You Stop
One of the most important things to understand about Wegovy is that it manages appetite rather than permanently resetting it. A 2025 systematic review published in The BMJ analyzed data from multiple studies and found that people taking newer medications in this class (including semaglutide) regained an average of about 9.9 kg (roughly 22 pounds) within the first year after stopping treatment. The average weight loss at the point of stopping was around 14.7 kg (about 32 pounds), meaning people regained roughly two-thirds of what they’d lost within 12 months.
The rate of regain was roughly 0.8 kg (about 1.8 pounds) per month. This doesn’t mean the drug “failed.” It means obesity involves persistent biological signals that push weight back up when treatment stops, similar to how blood pressure returns when someone stops taking blood pressure medication. Most current guidance treats Wegovy as a long-term or ongoing therapy rather than a short course.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent issue. Nausea, diarrhea, vomiting, and constipation top the list, with abdominal pain, bloating, acid reflux, and gas also commonly reported. In clinical trials, about 4.3% of patients on Wegovy stopped treatment because of gut-related side effects, compared to 0.7% on placebo. Nausea alone led 1.8% of patients to discontinue.
Other reported side effects occurring in at least 5% of patients include headache, fatigue, dizziness, and a tingling or altered skin sensation. Hair loss also appears on the list, though it’s generally temporary and likely related to the rapid weight loss itself rather than a direct drug effect. Most side effects are worst during the dose escalation phase and tend to improve once the body adjusts to the maintenance dose.